NCT02535312: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 12 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02535312 |
|---|---|
| Title | Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 8, 2016 |
| Completion date | Dec. 31, 2022 |
| Required reporting date | Dec. 31, 2023, midnight |
| Actual reporting date | Jan. 12, 2024 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 12 |